

SPEAKER AND MODERATOR BIOSKETCHES
WEBINAR 2 - Impact of the Dobbs Decision on Cancer Care:
Health System and Workforce Effects



Nicole Huberfeld, JD (Co-Moderator)
Boston University

Nicole Huberfeld is Edward R. Uteley Professor of Health Law at BU School of Public Health (BUSPH) and Professor of Law at BU School of Law, where she is also Co-Director of the BU Program on Reproductive Justice and affiliate faculty with the Center for Antiracism Research and the Medicaid Policy Lab. Her research studies the intersection of health law and constitutional law, examining law as a determinant of health with research on federalism, Medicaid, health reform, and reproductive care. She is the co-author of two leading health law casebooks and many national and international book chapters, law journal articles, peer-reviewed articles, and commentaries. Her work has been cited in judicial opinions by the U.S. Supreme Court and other federal and state courts. In 2019, Huberfeld won an Excellence in Teaching Award at BUSPH, and she was nominated for teaching awards in 2021 and 2022 at BU Law. Recently, she became Research Director for the Uniform Law Commission's Joint Editorial Board on Health Law. Media quotes include the New York Times, NPR, Washington Post, Bloomberg News, Reuters, Huffington Post, Talking Points Memo, National Law Journal, Congressional Quarterly, Politico, and Univision.



Kayte Spector-Bagdady, JD, MBioethics
(Co-Moderator)
University of Michigan

Kayte Spector-Bagdady, JD, MBioethics, is an Assistant Professor of Obstetrics and Gynecology and interim Co-Director at the Center for Bioethics and Social Sciences in Medicine and at the University of Michigan Medical School. She is also the Chair of the U-M Research Ethics Committee, the ethicist on the Human Data and Biospecimen Release Committee, and a clinical ethicist. She teaches the Responsible Conduct of Research as well as Research Ethics and the Law and is an Associate Editor of the American Journal of Bioethics.

The overarching goal of Prof. Spector's work is improving the governance of secondary research with health data and specimens to increase the accessibility of data and generalizability of advances across diverse communities. She is the PI of a National Human Genome Research Institute KO1 studying how and why geneticists select datasets for their research and a National Center for Advancing Translational Sciences RO1 on hospitals sharing patient data with commercial entities. Her recent articles have been published in The New England Journal of Medicine, Science, JAMA, and Nature Medicine, and her research or expertise has appeared in the NY Times, The Washington Post, The Wall Street Journal, TIME, and CNN.

Professor Spector was an Associate Director for President Obama’s Presidential Commission for the Study of Bioethical Issues, and is a former Board Member of the American Society for Bioethics & Humanities and practicing FDA law attorney. She graduated from the University of Pennsylvania Law School and School of Medicine after attending Middlebury College.



Barbara A. Goff, MD
University of Washington Medical Center

Dr. Barbara Goff received her MD from the University of Pennsylvania and completed her residency in Obstetrics and Gynecology at Brigham and Women’s Hospital. She then completed a fellowship in Gynecologic Oncology at Massachusetts General Hospital. Dr. Goff joined the faculty at the University of Washington in 1993 and was the Director of the Division of Gynecologic Oncology from 2005 to 2017. In August 2015 she was appointed Surgeon-in-Chief for the University of Washington Medical Center and in 2017 was appointed the Chair of the Department of Obstetrics and Gynecology where she leads a group of over 150 clinicians and scientists.

Dr. Goff has authored more than 150 articles and has written multiple textbook chapters on gynecologic malignancies. Her primary research interests have been evaluating novel markers for early detection of ovarian cancer and clinical trials for novel therapeutics in treatment of ovarian cancer. She specializes in surgical treatment of gynecologic malignancies, robotic surgery, chemotherapy for gynecologic cancers, clinical trials and early detection of ovarian cancer.



Courtney A. Schreiber, MD, MPH
University of Pennsylvania

Courtney A. Schreiber, MD, MPH, is the Emily and Stuart Mudd Professor of Obstetrics and Gynecology and Chief of the Division of Family Planning in the Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, and founding director of PEACE, the Pregnancy Early Access Center at Penn Medicine. She has devoted her career as a physician-scientist filling scientific and healthcare delivery gaps in women’s health and reproduction, with a focus on underserved women. Using translational, clinical, and health-services research methodologies to advance science and improve clinical outcomes, she has participated in more than 50 studies in reproductive health resulting in more than 100 peer-reviewed publications.

Dr. Schreiber also holds leadership roles for organizations that address knowledge gaps and improve women’s health care. She serves as Executive Director of The Perelman School of

Medicine's FOCUS on Health and Leadership for Women and a Senior Fellow, Leonard Davis Institute of Health. She co-leads Penn PROMOTES Research on Sex and Gender in Health a University-wide center that aims to illuminate the understanding of the wide-reaching and established sex differences in disease prevalence, phenomenology and treatment. She is the current Division Chair of the American Board of Obstetrics and Gynecology's Complex Family Planning Division. Dr. Schreiber applies the tools of academic medicine to provide innovative clinical care solutions and advance the science of women's reproductive health while nurturing the pipeline of future leaders.



Banu E. Symington, MD, MACP
Sweetwater Regional Cancer Center

Raised in Philadelphia and educated at the University of Pennsylvania, Dr. Symington was transplanted to the rural mountain west where she remains to this day. Medical director of a small rural cancer center, the only SWOG clinical trial site in Wyoming, Dr. Symington is a scientist, clinician, clinical trial enthusiast, and outspoken advocate for rural patients.



Jolyn Taylor, MD, MPH
University of Texas MD Anderson Cancer Center

Dr. Jolyn Taylor is an Assistant Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. Caring for women with gynecologic malignancies and improving the quality of healthcare delivery are her passions. Following graduation from Emory with a BA in Spanish and Chemistry, she completed her medical degree at NYU School of Medicine, residency in Obstetrics and Gynecology at NY Presbyterian Hospital Weill Cornell, fellowship at University of Texas MD Anderson Cancer Center and MPH at University of Texas School of Public Health. Currently, she administers chemotherapy and performs specialized surgery, including by open, laparoscopic and robotic techniques to treat women with gynecologic malignancy or complex gynecologic issues. She has been recognized by Press Ganey as in the Top 10% of providers for patient experience nation-wide (2021) and Top 1% (2022). Her research interests include Quality Improvement and Health Services Research focusing on disparities in healthcare.

She has authored and co-authored numerous articles in peer-reviewed journals. She was selected to serve as the Patient Safety Quality Officer for the Department of Gynecologic Oncology and Reproductive Medicine at MD Anderson since 2018. She also was chosen as the Division of Surgery Quality Officer at MD Anderson in 2021, becoming the first woman to serve in this role. In recognition of her contributions to improving the quality and safety of patient care, she was

awarded the MD Anderson President's Award for Clinical Quality Improvement in 2021. Dr. Taylor is also an active member of several national and international medical organizations and volunteers with non-profit organizations in Houston to raise awareness of gynecologic malignancies.



Ruqaiijah Yearby, JD, MPH
Ohio State University

Ruqaiijah Yearby, JD, MPH, is the inaugural Kara J. Trott Professor in Law at the Moritz College of Law. She earned her BS in Honors Biology from the University of Michigan, M.P.H. from Johns Hopkins School of Public Health, and her JD from Georgetown University Law Center. She started her career as an Assistant Regional Counsel for the U.S. Department of Health and Human Services.

Professor Yearby has received over \$5 million in grant funding from the National Institutes of Health and the Robert Wood Johnson Foundation. Her work has been published in the *American Journal of Bioethics*, *American Journal of Public Health*, *Health Affairs*, and the *Oxford Journal of Law and the Biosciences*. Her *American Journal of Bioethics* article, 'Race Based Medicine, Color Blind Disease: How Racism in Medicine Harms Us All,' was one of the top ten articles of the last three years (2020-2023) in that journal.

PLANNING GROUP BIOSKETCHES
WEBINAR SERIES - Impact of the Dobbs Decision on Cancer Care



Karen Basen-Engquist, PhD, MPH (Co-Chair)

The University of Texas MD Anderson Cancer Center

Karen Basen-Engquist, PhD, MPH, is the Annie Laurie Howard Research Distinguished Professor in the Department of Behavioral Science and the Director of the Center for Energy Balance in Cancer Prevention and Survivorship at The University of Texas MD Anderson Cancer Center. Dr. Basen-Engquist's research focuses on cancer survivors and high-risk individuals and investigates the role of health behavior interventions in improving physical functioning, optimizing quality of life, and reducing the risk of cancer, cancer recurrence, and other chronic diseases. In addition, she studies intervention methods for behavior change with a focus on distance-based and mHealth interventions and uses innovative real-time methods for assessing symptoms and behavior in cancer patients and survivors. She currently is the co-chair of LIVES, a national trial of a diet and physical activity intervention for ovarian cancer survivors, and has been a multiple PI and a co-investigator on grants to study the use of wearable and home-based sensors in cancer prevention and survivorship research. Her research on the benefits of physical activity for cancer survivors has been translated into a community program to increase physical activity among minority and medically underserved cancer survivors in Houston, Beaumont, Tyler, and El Paso, Texas, funded by the Cancer Prevention and Research Institute of Texas (CPRIT). Dr. Basen-Engquist's research center is working to expand energy balance research at MD Anderson by facilitating collaboration among investigators with interests in basic science, clinical, and population research related to physical activity, nutrition, obesity, and cancer.

Dr. Basen-Engquist is a member of the National Cancer Policy Forum at the National Academy of Medicine and has served as an organizer of NCPF workshops on incorporating physical activity and weight management programs throughout the cancer continuum, patient navigation, and health literacy. She is the past president of the American Society of Preventive Oncology.



Robin Yabroff, PhD, MBA (Co-Chair)

American Cancer Society

Robin Yabroff, PhD, is an epidemiologist and Scientific Vice President, Health Services Research, at the American Cancer Society. She conducts research on the economic burden of cancer; patterns of cancer care, including high cost prescription drugs; health insurance benefit design; and patient, provider, and health system factors associated with the quality and value of cancer care.

Dr. Yabroff has more than 20 years of health services research experience and currently has adjunct positions within the Department of Medicine, Johns Hopkins University, and the Rollins School of Public Health, Emory University. Prior to joining the American Cancer Society, she held positions within

the Office of Health Policy, Assistant Secretary for Planning and Evaluation (ASPE) in the US Department of Health and Human Services, the Health Services and Economics Branch of the National Cancer Institute, and the faculty of the Lombardi Cancer Center, Georgetown University. She earned her PhD in epidemiology from the Johns Hopkins School of Public Health and received an MBA from the University of Rochester.

Dr. Yabroff has co-authored over 300 peer-reviewed journal articles and invited editorials, commentaries, and book chapters. She is a Deputy Editor for the *Journal of the National Cancer Institute*, a founding member of the editorial board of the *Journal of Cancer Survivorship*, and a member of the editorial board of the *JCO Oncology Practice*. Dr. Yabroff has received multiple National Institutes of Health Merit Awards for her research leadership and mentorship.



Julie Gralow, MD, FACP, FASCO
American Society of Clinical Oncology (ASCO)

Dr. Gralow is the Chief Medical Officer and Executive Vice President of ASCO and brings to her role deep expertise in patient care, research, education, and global health.

Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance.

Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the Women's Empowerment Cancer Advocacy Network (WE CAN), she supports patient advocates in low- and middle-resource countries. In addition, she served as an adjunct professor in the University of Washington's Department of Global Health, as a member of the University of Washington's Breast Cancer Equity Initiative, as Medical Director for Women's Cancer-related Population Health at the University of Washington, and as an advisory council member for the Uganda Cancer Institute's adult Hematology/Oncology Fellowship Training Program. Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally.

She is a recognized leader in breast cancer clinical research, and has conducted clinical trials in breast cancer prevention, treatment, and survivorship. Dr. Gralow served in leadership roles for the SWOG Cancer Research Network funded by the National Cancer Institute (NCI), including as Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.

Before joining ASCO full-time, Dr. Gralow served the Society in a variety of volunteer and leadership roles, including chairing the ASCO Academic Global Oncology Task Force, co-chairing the ASCO Resource Stratified Guideline Advisory Group, and serving on the editorial board of the European Society of Medical Oncology (ESMO)/ASCO Global Curriculum in Medical Oncology.

She also has been involved with numerous other nonprofit organizations, including Team Survivor Northwest, an exercise and fitness program for woman cancer survivors which she co-founded in 1995 and serves as Team Physician; a medical advisory committee member for Cierra

Sisters African American Support Group; an advisory board member of Global Focus on Cancer; and a Board member of Peace Island Medical Center, a rural access hospital in Washington State.

Dr. Gralow received her bachelor's degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She trained in internal medicine at Brigham and Women's Hospital at Harvard Medical School and completed a medical oncology fellowship at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.



Roy S. Herbst, MD, PhD

Yale Comprehensive Cancer Center, Yale School of Medicine, and Smilow Cancer Hospital

Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT.

Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His leadership in targeted therapeutics resulted in a 2020 ASCO plenary talk and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the *New England Journal of Medicine*. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. In 2015 and again in 2020, his team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the NCI, which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies.

His work on "umbrella" trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies, such as Lung-MAP. He testified on the subject of modernizing clinical trials during the 21st Century Cures hearing before the US House of Representatives Subcommittee on Health and has served as a prominent figure in the public policy arena, for nine years having served as a member of the National Academy of Medicine's Cancer Policy Forum, for which he organized several meetings focused on policy issues in personalized medicine and tobacco control.

Dr. Herbst is a highly respected clinician- scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has authored or co-authored more than 350 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the *Journal of Clinical Oncology*, *Clinical Cancer Research*, *Lancet*, and the *New England Journal of Medicine*. Work published in *Nature* was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

He is a Fellow of the American Society of Clinical Oncology and a member of the American Association of Cancer Research (AACR), where he serves as an elected member of its board of directors and chairs the Tobacco Task Force. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. In 2019 he was elected to the International Association for the Study of Lung Cancer (IASLC) board of directors. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair of the Southwestern Oncology Group's (SWOG) Lung Committee.

For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th World Conference on Lung Cancer in Vienna, Austria. A team of Yale Cancer Center investigators led by Roy S. Herbst, MD, PhD, was awarded the 2018 Team Science Award from the Association for Clinical and Translational Science (ACTS) for its pioneering work in advancing our understanding of Immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy.



Nicole Huberfeld, JD
Boston University

Nicole Huberfeld is Edward R. Uteley Professor of Health Law at BU School of Public Health (BUSPH) and Professor of Law at BU School of Law, where she is also Co-Director of the BU Program on Reproductive Justice and affiliate faculty with the Center for Antiracism Research and the Medicaid Policy Lab. Her research studies the intersection of health law and constitutional law, examining law as a determinant of health with research on federalism, Medicaid, health reform, and reproductive care. She is the co-author of two leading health law casebooks and many national and international book chapters, law journal articles, peer-reviewed articles, and commentaries. Her

work has been cited in judicial opinions by the U.S. Supreme Court and other federal and state courts. In 2019, Huberfeld won an Excellence in Teaching Award at BUSPH, and she was nominated for teaching awards in 2021 and 2022 at BU Law. Recently, she became Research Director for the Uniform Law Commission's Joint Editorial Board on Health Law. Media quotes include the New York Times, NPR, Washington Post, Bloomberg News, Reuters, Huffington Post, Talking Points Memo, National Law Journal, Congressional Quarterly, Politico, and Univision.



Beth Y. Karlan, MD

University of California, Los Angeles, Jonsson Comprehensive Cancer Center

Beth Y. Karlan, MD, is Professor and Vice Chair of Women's Health Research in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine, University of California Los Angeles (UCLA). She is also the Director of Cancer Population Genetics at the UCLA-Jonsson Comprehensive Cancer Center. Dr. Karlan's research focuses on ovarian and other women's cancers as well as inherited cancer susceptibility. She has authored over 400 peer-reviewed research publications and for over ten years served as Editor-in-Chief of the scientific journals *Gynecologic Oncology* and *Gynecologic Oncology Reports*. She is an American Cancer Society Clinical Research Professor, has served in many national

leadership roles including president of the Society of Gynecologic Oncology, and has helped train a generation of physicians and scientists. In 2012, Dr. Karlan was appointed by the Obama White House to serve on the National Cancer Advisory Board and in 2015 she was elected to membership in the National Academy of Medicine. Dr. Karlan is a Fellow of the American Society of Clinical Oncology and a member of the National Cancer Policy Forum. Her contributions have been recognized by her peers with multiple awards including a Lifetime Achievement Award from the International Society of Gynecologic Cancer.



Alexander Melamed, MD

Massachusetts General Hospital

Alexander Melamed is an Assistant Professor in the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at New York-Presbyterian/ Columbia University Medical Center. He provides medical and surgical care to women with cancers of the reproductive system including ovarian, uterine, cervical, and vulvar cancer. His research focuses on improving outcomes among people with cancer and promoting the use of robust analytical methods for observational studies in oncology. Dr. Melamed's work has helped to define the role of minimally invasive surgery in gynecologic oncology and identified strategies that reduce unnecessary side effects in the treatment of ovarian cancer, and contributed to a shift in the international standard of care for

the treatment of early-stage cervical cancer. Dr. Melamed is the recipient of career development awards from the National Institute of Health's National Center for Advancing Translational Science, the American Society of Clinical Oncology's Conquer Cancer Foundation, and the Department of Defense's Ovarian Cancer Research Program.



Kayte Spector-Bagdady, JD, MBioethics
University of Michigan

Kayte Spector-Bagdady, JD, MBioethics is an Assistant Professor of Obstetrics and Gynecology and interim Co-Director at the Center for Bioethics and Social Sciences in Medicine and at the University of Michigan Medical School. She is also the Chair of the U-M Research Ethics Committee, the ethicist on the Human Data and Biospecimen Release Committee, and a clinical ethicist. She teaches the Responsible Conduct of Research as well as Research Ethics and the Law and is an Associate Editor of the American Journal of Bioethics.

The overarching goal of Prof. Spector's work is improving the governance of secondary research with health data and specimens to increase the accessibility of data and generalizability of advances across diverse communities. She is the PI of a National Human Genome Research

Institute KO1 studying how and why geneticists select datasets for their research and a National Center for Advancing Translational Sciences RO1 on hospitals sharing patient data with commercial entities. Her recent articles have been published in The New England Journal of Medicine, Science, JAMA, and Nature Medicine, and her research or expertise has appeared in the NY Times, The Washington Post, The Wall Street Journal, TIME, and CNN.

Professor Spector was an Associate Director for President Obama's Presidential Commission for the Study of Bioethical Issues, and is a former Board Member of the American Society for Bioethics & Humanities and practicing FDA law attorney. She graduated from the University of Pennsylvania Law School and School of Medicine after attending Middlebury College.